A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Kentucky, Lexington, Kentucky, United States
Contact: Study coordinator (Jamie Tarr) · Jamie.Tarr@uky.edu · 859-218-5151
Contact: Principal Investigator (Zhonglin Hao)
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Zheng Zhang) · Zzhang11@mdanderson.org · 713-792-0007
Contact: Principal Investigator (Bingnan Zhang)
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact: Study coordinator (David Qian) · dqian@fredhutch.org · 206-288-6938
Contact: Principal Investigator (Diane Tseng)
Novartis Investigative Site, Singapore, Singapore

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer (ES-SCLC) · Extensive Stage Lung Small Cell Cancer · Extensive-Stage Small-Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Changsha, China · Jinan, China

Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

Extensive-Stage Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung Cancer · Extensive-stage Small-cell Lung Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chengdu, China

A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Shenyang, China